The following is a summary of “Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium,” published in the December 2023 issue of Hematology by Vose et al.
Researchers conducted a retrospective study to delve into mantle cell lymphoma’s (MCL) clinical and pathological hallmarks in the immunochemotherapy era, aiming to refine predictive models for more accurate patient outcome predictions.
They collaborated in The North American Mantle Cell Lymphoma Project, a multi-institutional effort involving 23 institutions across North America, to assess and refine prognosticators for front-line therapy, which included 586 MCL cases diagnosed (2000 and 2012). MCL’s clinicopathological depths explored a voyage, charting treatment paths and refining outcome predictions. Thoroughly examined baseline parameters established and validated novel predictive models in an independent cohort of MCL cases.
The results showed that in front-line strategies, hematopoietic stem cell transplantation significantly influenced outcomes, with the most impact on overall survival (OS, P<0.0001) and progression-free survival (PFS, P<0.0001). P53 positive expression emerged as the most significant pathological parameter associated with inferior outcomes (P<0.0001 for OS and P=0.0021 for PFS). Predictive models, incorporating clinical, laboratory, and pathological parameters based on the baseline risk factor profile, demonstrated strong predictive power for survival in the validation cohort, resembling the training cohort’s stratification.
Investigators concluded that chemo triumphs over MCL, but the fight isn’t over. New prognostic tools sharpen treatment choices, promising even brighter futures for patients.
Source: jhoonline.biomedcentral.com/articles/10.1186/s13045-023-01520-7
